Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (11332)	11/1/2002 11:39:18 AM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

TORONTO, Nov. 1 /CNW/ - Dimethaid Research Inc. (TSX: DMX) today announced it has received gross proceeds of $1.25 million Cdn against the issuance of 624,694 shares of common stock pursuant to its private placement agreement with Acqua Wellington North American Equities Fund Ltd. To date the company has realized approximately $22 million from the sale of 5,869,421 common shares. In January 2001, Dimethaid entered into a private placement agreement with Acqua Wellington for equity financing covering the sale of up to $50 million of the company's common shares. The agreement was recently extended to November 30, 2002. About Dimethaid Research Inc. Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Québec and Wanzleben, Germany. The company develops and commercializes targeted therapeutic drugs that produce minimal side effects. Currently, Dimethaid's two platform technologies focus on transdermal drug delivery and revitalizing damaged immune systems. Products have potential applications in such wide-ranging areas as relieving osteoarthritic pain and combating the opportunistic infections associated with AIDS. For more information, please visit www.dimethaid.com.